Clinical trials: Chemical and Drug Induced Liver Injury
Tuberculosis Infection
Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs
Tuberculosis (TB) is the world's second leading cause of death from a single infectious agent after COVID-19. In 2022, TB was estimated to have affected 10.6 million people, of whom 1.3 million died because of it, despite the…
- Trial name
- TUBILI (NCT06539455)
- Testing
- standard anti-TB treatment
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- Stefania Cheli
Drug-induced Liver Injury
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
In this clinical study silymarin will be administered in different dosages and compared to placebo in order to address if the liver protecting features of silymarin, measured by changes of liver enzyme concentration, can be…
- Trial name
- SILVER (NCT05144217)
- Testing
- 2x 140 mg per day, 3x 280 mg per day, 1x 1120 mg
- Where
- 2 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Prof. Dr. Frank Behrens
Drug-induced Liver Injury
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
Drug re-administration or rechallenge should be avoided after drug-induced liver injury (DILI) to avoid recurrent and fatal injury. Rechallenge outcomes vary considerably by drug and patient subjects.
- Trial name
- NCT01584765
- Testing
- Prescription drugs with known hepatotoxicity
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Drug-Induced Liver Injury
Surveillance for Early Liver Injuries Caused by Yangxue Shengfa Capsule.
This is a prospective registry study to surveil early liver injuries caused by Yangxue Shengfa Capsule (YXSF Capsule) through a non-intervention observational way.
- Trial name
- NCT03113838
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Graves Disease, Graves Ophthalmopathy
Liver Function After Intravenous Methylprednisolone Administration
Graves' orbitopathy (GO) is a characterized by orbital soft tissue inflammation and oedema associated with glycosaminoglycan deposition and fibrosis. The most frequent cause is Graves' disease.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Liver Diseases, Liver Failure
- Trial name
- NCT03667157
- Testing
- every week IVMP therapy, very high doses IVMP therapy
- Volunteers
- 68 people
- Sponsor
- Medical University of Warsaw
Drug-induced Liver Injury
Correlative Cohort Study on the Clinical Features and Prognosis of Drug-induced Liver Injury
This was a retrospective study of a clinical observational cohort. The patients were admitted and definitely diagnosed by liver biopsy as drug-induced liver injury from September 2014 to September 2019, in the Second Department…
- Trial name
- NCT04302506
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Beijing Ditan Hospital
Acetaminophen, Drug Overdose
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
This study is a randomized, placebo-controlled double-blinded clinical trial of patients presenting with acetaminophen poisoning who are at increased risk of developing liver injury.
- Conditions
- Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning
- Trial name
- NCT05517668
- Testing
- Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Richard Dart, MD, PhD
Cancer, Drug Induced Liver Injury
Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
Cancer has moved from the tenth place to the second one over the last 100 years, being inferior to only cardiovascular diseases in morbidity and mortality.
- Trial name
- NCT05789797
- Testing
- Remaxol
- Where
- 5 sites in Russia
- Volunteers
- 368 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company